Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890762911> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W2890762911 endingPage "5536" @default.
- W2890762911 startingPage "5536" @default.
- W2890762911 abstract "5536 Background: In a phase II study of vaccination schedule in front-line combinatorial treatment of EOC (Braly JIT 2009), simultaneous day infusion dramatically enhanced the magnitude of induced immunity relative to a one week delayed schedule & other schedules historically evaluated. The current study is exploring the clinical & biological effects of the optimized 4 vaccine schedule relative to CP alone. Methods: Stage III/IV EOC patients (pts) optimally debulked to <1cm residual disease with CA125 >2x ULN were randomized to CP+O (cycle 1,3,5, & C5 +12 weeks) vs CP and followed for clinical outcomes and immune reponse. A total of at least 80 evaluable pts were required for 80% power to detect a difference of 45% vs 15% for a primary comparative analysis of induced CA125 specific T cell immunity using an IFN-γ ELISpot. Clinical evaluations and safety were considered secondary endpoints. Results: 97 pts (47 OV+SOC & 50 SOC) were accrued at 13 centers in US & Italy. Analysis of immune markers and long term clinical outcomes is ongoing. The median duration of follow up at time of this analysis was 26 months (m). There was no difference in safety outcomes between the treatment groups. Grade 3-4 toxicity was observed in 24 (52%) CP+O vs 28 (58%) C-P pts. Toxicities were typical of standard IV C-P chemotherapy. K-M Analysis of recurrence free survival (RFS) showed median RFS not estimable for CP+O [95% CI: 21.3, NE] vs 15.4 m [10.9,19.3] for CP (p=0.0009 log rank). In the interim analysis of survival (OS), 4 deaths have been observed in CP+O vs 16 in CP (log rank p=0.0025). Cox proportional hazard analysis finds consistent results across centers, and no imbalance in identified risk factors explanatory for the emerging outcome Conclusions: This study suggests simultaneous day vaccination with O on alternate cycles of front line CP leverages CP associated temporal change in the tumor microenvironment permitting an immune treatment effect to enhance the outcomes achievable with CP alone. This observation will be further characterized in ongoing translational studies and confirmed in a future phase III study. Clinical trial information: NCT01616303." @default.
- W2890762911 created "2018-09-27" @default.
- W2890762911 creator A5000568505 @default.
- W2890762911 creator A5002181160 @default.
- W2890762911 creator A5023897070 @default.
- W2890762911 creator A5027346475 @default.
- W2890762911 creator A5029359855 @default.
- W2890762911 creator A5029494360 @default.
- W2890762911 creator A5030229940 @default.
- W2890762911 creator A5032881252 @default.
- W2890762911 creator A5040422270 @default.
- W2890762911 creator A5040656664 @default.
- W2890762911 creator A5041551175 @default.
- W2890762911 creator A5049383880 @default.
- W2890762911 creator A5050846630 @default.
- W2890762911 creator A5061939825 @default.
- W2890762911 creator A5063907350 @default.
- W2890762911 creator A5064534384 @default.
- W2890762911 creator A5070572496 @default.
- W2890762911 date "2017-05-20" @default.
- W2890762911 modified "2023-10-03" @default.
- W2890762911 title "A randomized phase II study assessing an optimized schedule of oregovomab (O) anti-CA125 vaccination with carboplatin paclitaxel (CP) relative to CP alone in front-line treatment of optimally cytoreduced stage III/IV ovarian cancer (EOC)." @default.
- W2890762911 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.5536" @default.
- W2890762911 hasPublicationYear "2017" @default.
- W2890762911 type Work @default.
- W2890762911 sameAs 2890762911 @default.
- W2890762911 citedByCount "2" @default.
- W2890762911 countsByYear W28907629112019 @default.
- W2890762911 countsByYear W28907629112020 @default.
- W2890762911 crossrefType "journal-article" @default.
- W2890762911 hasAuthorship W2890762911A5000568505 @default.
- W2890762911 hasAuthorship W2890762911A5002181160 @default.
- W2890762911 hasAuthorship W2890762911A5023897070 @default.
- W2890762911 hasAuthorship W2890762911A5027346475 @default.
- W2890762911 hasAuthorship W2890762911A5029359855 @default.
- W2890762911 hasAuthorship W2890762911A5029494360 @default.
- W2890762911 hasAuthorship W2890762911A5030229940 @default.
- W2890762911 hasAuthorship W2890762911A5032881252 @default.
- W2890762911 hasAuthorship W2890762911A5040422270 @default.
- W2890762911 hasAuthorship W2890762911A5040656664 @default.
- W2890762911 hasAuthorship W2890762911A5041551175 @default.
- W2890762911 hasAuthorship W2890762911A5049383880 @default.
- W2890762911 hasAuthorship W2890762911A5050846630 @default.
- W2890762911 hasAuthorship W2890762911A5061939825 @default.
- W2890762911 hasAuthorship W2890762911A5063907350 @default.
- W2890762911 hasAuthorship W2890762911A5064534384 @default.
- W2890762911 hasAuthorship W2890762911A5070572496 @default.
- W2890762911 hasConcept C126322002 @default.
- W2890762911 hasConcept C143998085 @default.
- W2890762911 hasConcept C203014093 @default.
- W2890762911 hasConcept C203092338 @default.
- W2890762911 hasConcept C22070199 @default.
- W2890762911 hasConcept C2776090121 @default.
- W2890762911 hasConcept C2776694085 @default.
- W2890762911 hasConcept C2778239845 @default.
- W2890762911 hasConcept C2779053233 @default.
- W2890762911 hasConcept C2781451048 @default.
- W2890762911 hasConcept C29730261 @default.
- W2890762911 hasConcept C31760486 @default.
- W2890762911 hasConcept C535046627 @default.
- W2890762911 hasConcept C71924100 @default.
- W2890762911 hasConcept C8891405 @default.
- W2890762911 hasConcept C90924648 @default.
- W2890762911 hasConceptScore W2890762911C126322002 @default.
- W2890762911 hasConceptScore W2890762911C143998085 @default.
- W2890762911 hasConceptScore W2890762911C203014093 @default.
- W2890762911 hasConceptScore W2890762911C203092338 @default.
- W2890762911 hasConceptScore W2890762911C22070199 @default.
- W2890762911 hasConceptScore W2890762911C2776090121 @default.
- W2890762911 hasConceptScore W2890762911C2776694085 @default.
- W2890762911 hasConceptScore W2890762911C2778239845 @default.
- W2890762911 hasConceptScore W2890762911C2779053233 @default.
- W2890762911 hasConceptScore W2890762911C2781451048 @default.
- W2890762911 hasConceptScore W2890762911C29730261 @default.
- W2890762911 hasConceptScore W2890762911C31760486 @default.
- W2890762911 hasConceptScore W2890762911C535046627 @default.
- W2890762911 hasConceptScore W2890762911C71924100 @default.
- W2890762911 hasConceptScore W2890762911C8891405 @default.
- W2890762911 hasConceptScore W2890762911C90924648 @default.
- W2890762911 hasIssue "15_suppl" @default.
- W2890762911 hasLocation W28907629111 @default.
- W2890762911 hasOpenAccess W2890762911 @default.
- W2890762911 hasPrimaryLocation W28907629111 @default.
- W2890762911 hasRelatedWork W1967715255 @default.
- W2890762911 hasRelatedWork W2013653877 @default.
- W2890762911 hasRelatedWork W2053778437 @default.
- W2890762911 hasRelatedWork W2076107896 @default.
- W2890762911 hasRelatedWork W2382328728 @default.
- W2890762911 hasRelatedWork W2406976129 @default.
- W2890762911 hasRelatedWork W3047309708 @default.
- W2890762911 hasRelatedWork W3093101111 @default.
- W2890762911 hasRelatedWork W4312139687 @default.
- W2890762911 hasRelatedWork W84951532 @default.
- W2890762911 hasVolume "35" @default.
- W2890762911 isParatext "false" @default.
- W2890762911 isRetracted "false" @default.
- W2890762911 magId "2890762911" @default.
- W2890762911 workType "article" @default.